ZURICH (Reuters) - Shares in Swiss drugmaker Novartis AG (NOVN.VX: Quote, Profile, Research) were lower on Tuesday with traders citing a report from analysts at Prudential Securities, saying U.S. approval for diabetes drug Galvus could be delayed beyond an end-February deadline.
